Perspectives

Ugo Moretti
Focus Farmacovigilanza 2017;96(3):1
At the end of February 2017, the Italian Agency of Medicines, AIFA, announced on its website (http://www.agenziafarmaco.gov.it/) the launch of a new modality for reporting suspect adverse reactions to drugs and vaccines. Healthcare professionals and citizens in Italy can now report directly from...
Michele Gangemi1, Ugo Moretti2 and Giampaolo Velo3
Focus Farmacovigilanza 2016;95(11):1
Focus Farmacovigilanza has already covered the phenomenon of vaccination drop and its possible solutions.1 This article aims at discussing the consequences for public health caused by the choice of not-vaccinating. After all, adverse-reaction reports do not regard the health of a single person only...
John Dowden
Focus Farmacovigilanza 2016;94(9):1
Autodromo Nazionale Monza is a famous fast track. It has also been the place of many injuries and deaths. Just like motor racing, drug development can be dangerous ̶ go too fast and there may be disaster. In drug regulation a fast track approval process aims to accelerate the availability of...
Ivor Ralph Edwards1 and Giampaolo Velo2
Focus Farmacovigilanza 2016;93(3):7
What are we talking about? To get started it is worth looking at the ways in which “bureaucracy” is used. According to Google definitions bureaucracy has 4 meanings: System of government in which most of the important decisions are taken by state officials rather than by elected representatives...
Hervé Le Louët*(MD, PhD), Jean Michel Dogné (PD, PhD)**
Focus Farmacovigilanza 2016;92(1):1
1) Background.In European Union (EU), the Burden of Adverse Drug Reactions (ADRs) is a major concern of public health with 5% of all hospital admissions due ADRs and 5% of all hospital patients suffering an ADR. Today ADRs are the 5th most common cause of hospital death with 197 000 deaths per year...
Roberto Satolli
Focus Farmacovigilanza 2015;91(12):1
The Italian Medicines Agency (AIFA) was founded in 2004 under the management of Nello Martini and grew enriching its regulatory mandate with complementary activities such as funding independent research and providing information/education for professionals. One of the biggest damage caused by the...
Ugo Moretti1, Roberta Opri2 and Giovanna Zanoni2
Focus Farmacovigilanza 2015;91(11):2
The alarming data Last September, Paidòss (National Observatory on child and teenage health) presented at its National Convention a research that involved 1,000 parents of children aged 6 or less, interviewed between May and June 2015, and was conducted by Datanalysis (a public opinion research...
Michael Rawlins
Focus Farmacovigilanza 2015;90(9):1
Background NICE – the National Institute for Clinical Excellence – was established in 1999 by the UK’s Department of Health as an independent body free from political (or other) vested interests. Its remit was to provide advice (“guidance”) to enable health professionals, working in the...
Roberto Leone and Lara Magro
Focus Farmacovigilanza 2015;89(8):1
Earlier this year, at the presentation of the OsMed/AIFA report on drug consumption in Italy, health Minister Lorenzin expressed "grave concern at the increased consumption of opiates." Are Minister's concerns justified? Were we not the country with one of the lowest morphine consumption rates in...
Giampaolo Velo, Mauro Venegoni, Pietro Dri
Focus Farmacovigilanza 2015;88(5):1
The bulletin “Focus Farmacovigilanza” has always been particularly sensitive to the conflict of interest issue, to the point of reporting to the reader even the possible conflicts concerning the sources used in the various articles. It’s worth reminding that “Focus Farmacovigilanza” is not a...

Pages